(0.05%) 5 471.90 points
(0.07%) 39 138 points
(0.36%) 17 782 points
(-0.07%) $80.77
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.25%) $28.94
(3.61%) $1 022.00
(0.29%) $0.936
(0.71%) $10.68
(0.46%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders...
Stats | |
---|---|
今日成交量 | 1 198 |
平均成交量 | 0 |
市值 | 4.44M |
EPS | $-0.600 ( Q1 | 2024-05-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0100 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Silva Raul R. | Buy | 1 000 | Stock Option (right to Buy) |
2023-09-29 | Silva Raul R. | Buy | 10 000 | Stock Option (right to Buy) |
2023-09-15 | Callahan Jennifer L. | Buy | 5 000 | Common Stock |
2023-09-08 | Werth Peter J. | Buy | 6 838 235 | Pre-Funded Warrant (right to buy) |
2023-08-11 | Werth Peter J. | Buy | 1 823 155 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 79 transactions |
Buy: 10 002 264 | Sell: 8 300 |
Cingulate Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2023 |
营收: | $0 |
毛利润: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2022 |
营收: | $0 |
毛利润: | $-621 993 (0.00 %) |
EPS: | $-31.57 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company\'s lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。